FREQUENCY AND CHARACTERISTICS OF ADVERSE REACTIONS TO SECOND LINE ANTI-TUBERCULOSIS DRUGS IN THOSE ILL WITH MULTIPLE DRUG RESISTANT TUBERCULOSIS
https://doi.org/10.21292/2075-1230-2017-95-10-63-67
Abstract
During the chemotherapy, frequency and characteristics of adverse reactions to second line anti-tuberculosis drugs in 324 patients ill with multiple drug resistant tuberculosis were investigated. The majority of patients (319 - 98.4%) had various adverse reactions to second line anti-tuberculosis drugs.
Adverse reactions caused by one or two drugs provided no negative impact on treatment efficiency. As the number of poorly tolerated drugs increased, the level of favorable treatment outcomes went down, whereby the significant confident correlation was observed between adverse outcomes and poor tolerance of 3 and more anti-tuberculosis drugs p = 0.000, r = +> 0.9. There was doubtful correlation observed between poor tolerance anti-tuberculosis drugs and cases deaths (p > 0.05, r = +> 0.3). The doubtful correlation was also observed between cases of lost from treatment and poor tolerance of anti-tuberculosis drugs, p > 0.05, r = +> 0.3.
About the Author
A. A. Toktogonova
National Phthisiology Center
Kyrgyzstan
Kyrgyzstan
Leading Researcher of Therapy Department,
Bishkek
References
1. Alisherov A.Sh. State of TB services in the Kyrgyzstan Republic. TsAMJ, vol. XVII, Appendix 1, 2011, pp. 53. (In Russ.)
2. Аlisherov А.SH., Toktogonova А.А., Esentaeva E. Data on multiple drug resistant tuberculosis in the Kyrgyzstan Republic. Meditsinskie Kadry XXI v., 2011, no. 1, pp. 60-64. (In Russ.)
3. Аstakhova А.V., Lepakhin V.K. Neblagopriyatnye pobochnye reaktsii i kontrol bezopasnosti lekarstv: Rukovodstvo po farmakonadzoru. [Adverse reactions and drug safety monitoring. Pharmacovigilance guidelines]. Moscow, Kogoto-Tsentr Publ., 2004, 200 p.
4. Rich L.М., Kvonzhune J.S., Gilman R.H. et al. Rukovodstvo po lecheniyu tuberkuleza s mnozhestvennoy lekarstvennoy ustoychivostyu. [Guidelines on treatment of multiple drug resistant tuberculosis]. Partners in Health, 2003, 2nd ed., 2013, 302 p.
5. Toktogonova A.A. Prevalence of MDR TB in the Kyrgyzstan Republic. Phthisiopulmonology, 2013, no. 1 (22), pp. 29-32. (In Russ.)
6. Buziashvili M.G., Mirtskhulava V., Kipiani M. et al. Adverse reactions associated with injectable second-line anti-tuberculosis drugs among patients with M/XDR-TB in Tbilisi. Int. J. Tuberc Lung Dis., 2015, vol. 19, no. 12, pp. 486. http://capetown.worldlunghealth.org/Abstract_Book_ 2015-Web.pdf
7. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. WHO, Geneva. 2014, 403 p.
8. Nathanson E., Gupta R., Huamani P. et al. Adverse events in the treatment of multidrug-resistant tuberculosis: Results from the DOTS-Plus initiative. Int. J. Tuberc. Lung Dis., 2004, vol. 8, no. 11, pp. 1382-1384. www.ncbi.nlm.nih. gov/pubmed/15581210
Review
For citations:
Toktogonova A.A. FREQUENCY AND CHARACTERISTICS OF ADVERSE REACTIONS TO SECOND LINE ANTI-TUBERCULOSIS DRUGS IN THOSE ILL WITH MULTIPLE DRUG RESISTANT TUBERCULOSIS. Tuberculosis and Lung Diseases. 2017;95(10):63-67. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-10-63-67
Views:
1311
Email this article 